RV001: An anti-metastatic cancer vaccine

Project Information

RV001

Grant agreement ID: 879817

DOI 10.3030/879817

Project closed

EC signature date 27 September 2019

Start date 1 October 2019

End date 30 September 2022

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost € 5 273 880,00

EU contribution € 2 499 900,00

Coordinated by

RHOVAC APS
Denmark

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Documents, reports (1)

Dissemination and communication plan

D42 Dissemination and communication plan M6 updated every six months

Websites, patent fillings, videos etc. (1)

Project website (M3)

D4.1 Project website (M3)

Publications

Peer reviewed articles (1)

Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial

Author(s): Juliane Schuhmacher, Sonja Heidu, Torben Balchen, Jennifer Rebecca Richardson, Camilla Schmeltz, Jesper Sonne, Jonas Schweiker, Hans-Georg Rammensee, Per Thor Straten, Martin Andreas Røder, Klaus Brasso, Cécile Gouttefangeas
Published in: Journal for ImmunoTherapy of Cancer, Issue 8/2, 2020, Page(s) e001157, ISSN 2051-1426
Publisher: Journal of Immunotherapy of cancer
DOI: 10.1136/jitc-2020-001157